Precision BioSciences (DTIL) Competitors $5.07 -0.13 (-2.50%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$5.07 0.00 (0.00%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. URGN, CRDF, CGC, PROK, GNFT, DBVT, AVTE, YMAB, ACTU, and ENGNShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include UroGen Pharma (URGN), Cardiff Oncology (CRDF), Canopy Growth (CGC), ProKidney (PROK), Genfit (GNFT), DBV Technologies (DBVT), Aerovate Therapeutics (AVTE), Y-mAbs Therapeutics (YMAB), Actuate Therapeutics (ACTU), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Its Competitors UroGen Pharma Cardiff Oncology Canopy Growth ProKidney Genfit DBV Technologies Aerovate Therapeutics Y-mAbs Therapeutics Actuate Therapeutics enGene UroGen Pharma (NASDAQ:URGN) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, community ranking, valuation, risk and analyst recommendations. Which has more risk & volatility, URGN or DTIL? UroGen Pharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.48, indicating that its share price is 48% more volatile than the S&P 500. Does the media favor URGN or DTIL? In the previous week, UroGen Pharma had 51 more articles in the media than Precision BioSciences. MarketBeat recorded 53 mentions for UroGen Pharma and 2 mentions for Precision BioSciences. Precision BioSciences' average media sentiment score of 0.77 beat UroGen Pharma's score of 0.07 indicating that Precision BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment UroGen Pharma 2 Very Positive mention(s) 6 Positive mention(s) 37 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Precision BioSciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is URGN or DTIL more profitable? Precision BioSciences has a net margin of 11.48% compared to UroGen Pharma's net margin of -129.11%. UroGen Pharma's return on equity of 0.00% beat Precision BioSciences' return on equity.Company Net Margins Return on Equity Return on Assets UroGen Pharma-129.11% N/A -47.94% Precision BioSciences 11.48%-23.69%-6.98% Do institutionals and insiders believe in URGN or DTIL? 91.3% of UroGen Pharma shares are held by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are held by institutional investors. 5.1% of UroGen Pharma shares are held by company insiders. Comparatively, 4.5% of Precision BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts recommend URGN or DTIL? UroGen Pharma currently has a consensus price target of $23.14, suggesting a potential upside of 217.03%. Precision BioSciences has a consensus price target of $47.00, suggesting a potential upside of 827.02%. Given Precision BioSciences' stronger consensus rating and higher probable upside, analysts plainly believe Precision BioSciences is more favorable than UroGen Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score UroGen Pharma 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, URGN or DTIL? Precision BioSciences has lower revenue, but higher earnings than UroGen Pharma. Precision BioSciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUroGen Pharma$91.87M3.66-$102.24M-$3.18-2.30Precision BioSciences$51.14M1.10-$61.32M-$2.01-2.52 Does the MarketBeat Community believe in URGN or DTIL? UroGen Pharma received 285 more outperform votes than Precision BioSciences when rated by MarketBeat users. Likewise, 74.27% of users gave UroGen Pharma an outperform vote while only 69.06% of users gave Precision BioSciences an outperform vote. CompanyUnderperformOutperformUroGen PharmaOutperform Votes38174.27% Underperform Votes13225.73% Precision BioSciencesOutperform Votes9669.06% Underperform Votes4330.94% SummaryUroGen Pharma beats Precision BioSciences on 10 of the 19 factors compared between the two stocks. Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DTIL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$56.22M$3.09B$5.57B$8.63BDividend YieldN/A1.58%5.28%4.18%P/E Ratio84.5133.3227.1220.06Price / Sales1.10469.84412.30157.10Price / CashN/A168.6838.2534.64Price / Book1.123.457.064.70Net Income-$61.32M-$72.35M$3.23B$247.88M7 Day Performance-1.17%6.23%2.86%2.63%1 Month Performance-2.87%16.53%9.07%6.36%1 Year Performance-56.85%-16.90%31.45%14.05% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.2078 of 5 stars$5.07-2.5%$47.00+827.0%-57.8%$56.22M$51.14M84.51200URGNUroGen Pharma4.6818 of 5 stars$4.84+14.2%$27.43+466.7%-44.2%$223.16M$91.87M-1.54200Trending NewsShort Interest ↓High Trading VolumeCRDFCardiff Oncology1.8414 of 5 stars$3.35-1.8%$12.00+258.2%+31.2%$222.86M$587K-3.5620CGCCanopy Growth2.388 of 5 stars$1.21-8.3%$2.00+65.3%-78.6%$222.48M$276.75M-0.323,150Gap UpHigh Trading VolumePROKProKidney2.4428 of 5 stars$0.75+3.2%$5.00+570.3%-61.4%$218.32M$306K-1.363Positive NewsGNFTGenfit2.5783 of 5 stars$4.34-3.8%$13.00+199.7%-17.0%$216.83M$67.00M0.00120Positive NewsShort Interest ↓DBVTDBV Technologies3.4401 of 5 stars$7.74-7.3%$14.75+90.6%+72.7%$212.00M$15.73M-1.7280News CoverageAVTEAerovate Therapeutics2.0323 of 5 stars$7.25+2.3%$78.75+986.2%-99.1%$210.14MN/A-2.4220Positive NewsHigh Trading VolumeYMABY-mAbs Therapeutics3.7663 of 5 stars$4.74+3.0%$15.60+229.1%-59.0%$208.31M$88.66M-8.78150Analyst RevisionACTUActuate TherapeuticsN/A$10.59-11.0%$20.50+93.6%N/A$207.78MN/A0.0010High Trading VolumeENGNenGene2.6336 of 5 stars$3.98+3.6%$23.29+485.1%-63.2%$202.89MN/A-6.8631Gap Up Related Companies and Tools Related Companies UroGen Pharma Alternatives Cardiff Oncology Alternatives Canopy Growth Alternatives ProKidney Alternatives Genfit Alternatives DBV Technologies Alternatives Aerovate Therapeutics Alternatives Y-mAbs Therapeutics Alternatives Actuate Therapeutics Alternatives enGene Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DTIL Stock Free DTIL Stock Alerts